Comparative Evaluation of Liposomal Albendazole and Tablet-Albendazole Against Hepatic Cystic Echinococcosis

Abstract

In this study, we aimed to compare the clinical efficacy of liposomal albendazole (L-ABZ) and tablet-albendazole (T-ABZ) for the treatment of human hepatic cystic echinococcosis (CE).Sixty patients with single cyst (CE1) or daughter cyst (CE2) were included in this study and were nonrandomly divided into the L-ABZ group (n = 30, 10 mg/kg per day, p.o., b.i.d.) and T-ABZ group (n = 30, 12–20 mg/kg per day, p.o., b.i.d.), respectively. The treatment duration lasted for 6 months, during which dynamic follow-up was carried out to evaluate the clinical efficacy through calculating the total effective rates (TERs). Measurement data and numerous data were analyzed by the chi-square test. Two-sided tests were performed for all the statistical tests.In our study, 2 patients were lost in the follow-up in the L-ABZ group. One patient was lost in the follow-up in the T-ABZ group, and 1 patient was withdrawal from the study due to receiving surgery. Significant difference was identified in the 3-month TERs of L-ABZ group and T-ABZ group (33.3% vs 76.7%, P < 0.05). Also, remarkable difference was noted in the 6-month TERs in the L-ABZ group and T-ABZ group (66.7% vs 93.3%, P = 0.01). No statistical difference was noticed in the incidence rate of adverse reactions in both groups (P > 0.05).Based on our study, both T-ABZ and L-ABZ are effective for treating human CE. The TER in the L-ABZ group is superior to that of T-ABZ.

Comparative Evaluation of Echinococcus Serology with Cytology for the Diagnosis of Hepatic Hydatid Disease

“…Echinococcosis or hydatid disease (HD) is a parasitic illness caused by infection with dog tapeworms (Echinococcus granulosus and Echinococcus multilocularis) in its larval stage. 1 HD global prevalence is estimated at 2 to 3 million human cases, with an estimated mortality rate of 2 to 4% per 100 inhabitants. 2,3 HD is endemic in more than 100 countries globally, with the highest prevalence found in Mediterranean regions, parts of Russia, central Asia, China, Australia, parts of South America, and Africa.…”

Current status of diagnosis and treatment of hepatic echinococcosis

“…Cystic echinococcus (CE) is a parasitic illness, caused by infection with Echinococcus granulosus ( E. granulosus ) in its larval stage[ 1 ]. Although the disease occurs worldwide, it is endemic in Africa, South America, and Eurasia[ 2 - 4 ].…”

An alternative mebendazole formulation for cystic echinococcosis: the treatment efficacy, pharmacokinetics and safety in mice

“…Although no acute toxicity of MBZ-OS had been seen in this experiment, a long-term toxicity test is still necessary in the following study. In the treatment of hydatid diseases, the benzimidazoles were considered safe with occasional side effects [37][38][39]. In China, albendazole-emulsion is the dominant clinical formulation for patients with echinococcosis.…”